Endpoints
DISEASE, LYMPH NODE METASTASIS
The primary endpoint was the rate of IGL, defined as attempt to selectively localize the clipped node under imaging guidance. Secondary endpoints assessed IGL use by country, year, palpable versus non-palpable disease, and type of clip. Further endpoints investigated the impact of IGL during TAS on number of removed lymph nodes and positive lymph nodes, as well as size of removed lymph node metastasis and rate of residual nodal disease removed during immediate back-up ALND that followed TAS according to the 1:1 randomization in the main TAXIS trial.